GLOBAL
Ecron Acunova, a clinical research organization with offices across Europe, in India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow, Russia in October 2009. Mrs Galyna Andriyko has been named as General Manager. She will lead the development of the Russian office operations.
“Russia has substantial unexplored capabilities. With its 141 million population and well recognized experience in clinical trials, Russia allows high recruitment rates, low drop-out rates and high quality data, to be obtained by dedicated medical professionals. With Mrs Andriyko’s expertise, we look forward to strengthening clinical trials in this region,” said Dr. Antal K. Hajos, Managing Director & CEO, Ecron Acunova, Europe said
Mrs Andriyko has successfully set up operations in Ukraine. The clinical team will be headed by Dr. Vlad Linievych, a physician, who has over 13 years of experience in industry. Ecron Acunova has been active in Russia for several years via collaborations and has 23 years of clinical expertise. Across Europe alone, Ecron Acunova covers 14 countries.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.